Medlogix designs, manufactures, and sells innovative hyperthermia systems for oncology, physiotherapy, and sports medicine. Medlogix began its activities in 2009 with the sale of the ALBA ON 4000 device for superficial hyperthermia.
From 2010 onwards Medlogix has started a series of technical and scientific collaborations with several excellent university centers, such as the University of Tor Vergata (Rome, Italy), the AMC/University of Amsterdam (Amsterdam, Netherlands), ErasmusMC (Rotterdam, Netherlands), the Czech Technical University (Prague, Czech Republic), for the development of innovative and technically advanced customized projects in the field of oncological hyperthermia.
From the collaborations with these academic institutions, Medlogix Srl has managed to develop and market the most advanced hyperthermia products for the radiation oncology field.
The ALBA devices are now installed in radiotherapy departments of top cancer hospitals and research centers in Europe, the Middle East, and Asia.
From 2012 to 2018 Medlogix has developed ALBA 4D, the most advanced phased array system for oncological deep hyperthermia in the world, which is now CE marked and installed in prestigious cancer centers in Europe and soon in Asia.
Medlogix is based in Rome’s Tiburtino Technology Park, well known for companies partnering in precision engineering and electronics, radar technology, and space telecommunications.
Medlogix has expert staff for hardware and software design, dedicated exclusively to the development of innovative technology for hyperthermia in oncology.